David Mauro, M.D., Ph.D., Chief Medical Officer
David Mauro, M.D., Ph.D. brings more than 20 years of oncology drug development experience to Codiak, including directing translational, early- and late-stage development for more than 25 Investigational New Drug candidates in the past decade. Most recently, he served as chief medical officer of Prelude Therapeutics where he oversaw all aspects of clinical development, including clinical operations, clinical pharmacology, translational, statistics and regulatory affairs for the company’s pipeline of targeted small molecule therapeutics for cancer. Prior positions include chief medical officer roles at Checkmate Pharmaceuticals and Advaxis Immunotherapies, both oncology immunotherapy companies. Earlier in his career, Dr. Mauro held positions of increasing responsibility within the clinical and medical affairs teams at Merck, Bristol Myers Squibb and Becton Dickinson. Dr. Mauro received a B.S. in biochemistry from Cornell University, an M.D./Ph.D. from Temple University School of Medicine and completed his residency in anatomic pathology at the National Institutes of Health’s National Cancer Institute.